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Abstract
We have previously reported that a single injection of endotoxin, lipopolysaccharide (LPS, 5 mg/kg,
i.p.), causes a delayed and progressive loss of TH-IR neurons in the substantia nigra (SN) in C57BL/
six male mice. In this study, we determined sex differences and behavioral deficits accompanying
the loss of TH-IR neurons in response to peripheral LPS injection. A single injection of LPS (5 mg/
kg, i.p.) failed to produce any loss of TH-IR neurons in the SN of female mice over a 12-month
period. To determine if multiple-injections were required, female mice received five injections of
LPS (5 mg/kg, i.p.) at either weekly or monthly intervals. Behavioral motor ability and TH-IR
neuronal loss were determined after the first injection of LPS. We found significant differences in
both behavioral activities and neuronal loss between these two injection paradigms. Between 7 and
20 months after the first injection of LPS, progressive behavioral changes, measured by rotor-rod
and open-field activities, and neuronal loss in SN were observed in monthly injected, but not in
weekly injected mice. In addition, reduced rotor-rod ability in monthly injected mice were restored
following treatment of L-dopa/carbidopa (30 mg/3 mg/kg), i.p.). Approximately 40 and 50% loss of
TH-IR neurons at 9 and 20 months, respectively, was observed after exposure to LPS, suggesting
that the behavioral deficit is related to loss of dopamine function in the nigrastriatal pathway. More
intense immuno-staining of α-synuclein and inflammatory markers were detected in brain sections
exposed to LPS. In conclusion, these results show that multi-LPS monthly injections can induce a
delayed and progressive loss of TH-IR neurons andmotor deficits which resemble the progressive
nature of Parkinson’s disease. Further, the present study reveals a clear sex difference: female mice
are more resistant to LPS than male mice. Repeated monthly LPS injections are required to cause
both motor behavioral deficits and DA neuronal loss in female mice.
Keywords
Lipopolysaccharide; Neurodegeneration; Parkinson’s disease; TH-IR neurons; Rotarod test
*Corresponding author. Tel.: +1 919 541 2358; fax: +1 919 541 0841. E-mail address: hong3@niehs.nih.gov (J.-S. Hong).
1These authors contributed equally to this work.
NIH Public Access
Author Manuscript
Neurotoxicology. Author manuscript; available in PMC 2009 October 15.
Published in final edited form as:














The hallmark of Parkinson’s disease (PD) is characterized by a progressive loss of
dopaminergic (DA) neurons in the substantia nigra (SN). The symptoms of PD include resting
tremor, stiffness or rigidity, bradykinesia (Jellinger, 2001; Shulman, 2007). The etiology of
PD as well as the precise mechanism underlying the progressive loss of DA neurons has
remained unknown. So far, numerous rodent PD models ranging from 6-hydroxydopamine,
MPTP, pesticides (Betarbet et al., 2002; Shimohama et al., 2003) such as rotenone (Betarbet
et al., 2000; Testa et al., 2005) and paraquat (Dinis-Oliveira et al., 2006) to endotxoins (Ling
et al., 2002) have been developed. These models reproduce some key features of PD, and are
useful in studying the mechanism underlying the pathogenesis of PD. Few of these models
address the progressive nature of the loss of DA neurons and motor function deficits.
To determine the role of microglia in inflammation-related neurodegeneration, we have used
lipopolysaccaride (LPS), an endotoxin from the cell walls of gram-negative bacteria, as a tool
to create a rodent PD model which shows the characteristic of delayed and progressive nature
of neurodegeneration. We previously reported that intra-nigral infusion of LPS through a mini-
osmotic pump for 2 weeks produced a delayed, progressive and selective loss of nigral DA
neurons(Gao et al.,2002). Our study shows that neurodegeneration is caused by the release of
pro-inflammatory factors such as free radicals, cytokines from over-activated microglia by
LPS (Gao et al., 2002). We recently reported that a single systemic injection of LPS produced
a delayed (7 months after LPS injection) and progressive loss (7–10 months) of nigral DA
neurons in mice (Qin et al., 2007). However, mechanistic studies revealed that neurotoxicity
was not due to the direct effect of LPS, but rather the toxic effect was mediated through entry
of pro-inflammatory cytokines such as TNFα from peripheral blood, which in turn triggers the
activation of microglia in the brain. The end results of our systemic LPS study resemble in
uterus exposure of developing fetuses to LPS, which results in lesions of nigro-striatal
dopaminergic system in neonates (Ling et al., 2002, 2006). Results from the above-mentioned
LPS rodent PD models indicate a critical role of inflammation in the delayed and progressive
nature of the loss of DA neurons in PD.
In this study, we determined sex differences and behavioral deficits accompanying the loss of
TH-IR neurons in response to peripheral LPS injection in mice. We found that female mice
are less responsive to LPS injection and repeated injections of LPS were required to produce
DA neuron loss in female mice. In addition, we found significant differences in both rotarod
motor ability and neuronal loss depending on the injection time intervals. Progressive
behavioral changes, measured by rotor-rod and open-field activities, and DA neuronal loss in
SN were observed in monthly injected, but not in weekly injected mice.
2. Materials and methods
2.1. Animals
Animal studies were performed in accordance with National Institutes of Health Guidelines,
approved by the Institute’s Animal Care and Use Committee, and NIH guidelines were
followed.
Eight-week male and female C57BL/six (20–22 g) mice were purchased from Jackson
Laboratories (Bar Harbor, ME). The animals were fed on a standard diet and tap water ad
libitum for 2 weeks prior to experiments. Environmental conditions were standardized,
including a room temperature of 21.8 °C and 12-h artificial lighting cycle.
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Lipopolysaccharide (strain O111:B4) was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Rabbit anti-tyrosine hydroxylase polyclonal antibody and rabbit polyclonal
antibody against interleukin-6 were from Chemicon (Temecula, CA, USA). Rat anti-mouse
CD45 was from Serotec Inc. (Raleigh, NC, USA). α-Synuclein mouse monoclonal antibody
was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). All other reagents came from
Sigma Chemical Co. (St. Louis, MO, USA).
2.3. Injection of LPS and L-dopa/carbidopa
We injected three batches of C57BL/six mice. Batch 1, male and female mice were injected
with a single dose of LPS (5 mg/kg, i.p.); Batch 2, female mice were weekly injected with five
doses of LPS (5 mg/kg, i.p.); Batch 3, female mice were monthly injected with two to five
doses of LPS (5 mg/kg, i.p.). At 12 months following the first LPS/saline administration in
monthly LPS-injection group, the mice were administered saline (1 ml/kg, i.p.), or L-dopa/
carbidopa (30 mg/3 mg/kg, i.p.).
2.4. Rotarod test
The rotorod apparatus (Rotamex, Columbus Instruments, Columbus, OH) was used to evaluate
the ability of staying on the rotating rod. Mice were transported (within their home cage) to
acclimate to the testing room for 1 h prior to testing started. The parameters of rotor-rod system
include start speed, acceleration and highest speed (2 rpm, accelerate 2 rpm/5 s, 40 rpm). Each
mouse was placed on the confined section of the rod, turn on the rotarod that begins to rotate
with a smooth increase in speed from 2 rpm. Mice received three consecutive trails. The rest
period between each trial was 2 min. The mean latency for the three trails was used for the
analysis. The latency to fall was measured in seconds. In all trials, if the mouse did not fall
from the rod, it was removed from the rod after 2 min.
2.5. Open-field test
Open-field measuring system (Opto-Max, Columbus Instruments, Columbus, OH) was used
for measuring animal’s activity, this system can automatically record all activities of the
animal. Mice were transported (within their home cage) to acclimate to the testing room for 1
h prior to testing started. Control and five-time monthly LPS injection animals were put in the
separated testing field, and 30-min locomotor activity was automatically recorded. Endpoints
for analysis are ambulatory activity, total activity, and traveled distance.
2.6. Immunohistochemistry
Mice were perfused transcardially with saline followed by 4% paraformaldehyde in phosphate
buffer (0.1 M, pH 7.4). The brains were removed, postfixed in 4% paraformaldehyde for 24 h,
and then transferred to 30% sucrose in 0.1 MPBS for at least 24 h before sectioning for
histochemical analysis, according to our standard protocol (Boger et al., 2006). Coronal
sections through the striatum and SN (35 µm for TH and α-synuclein; 45 µm for CD45 and
IL-6) were cut and processed for free-floating immunohistochemistry using a rabbit polyclonal
antibody against tyrosine hydroxylase (TH; 1:1000), a rat anti-mouse antibody against the
inflammatory MHC Class II-induced cluster differentiation marker, CD45 (1:1000), a rabbit
polyclonal antibody against interleukin-6 (1:10,000) and α-synuclein mouse monoclonal
antibody (1:100). Immunodetection was performed using the avidin–biotin–
immunoperoxidase method (Boger et al., 2006; Granholm et al., 1997a,b). Briefly, after a 5-
min pretreatment with 2% Triton-X to allow penetration into the tissue, a subset of sections
from each mouse was incubated in the primary antisera for 24 h at 4 °C. The sections were
then rinsed and incubated for 1 h in biotin-conjugated goat anti-rabbit (TH and IL-6) IgG or
goat anti-rat (CD45) IgG, or goat anti-mouse (α-synuclein) IgG, rinsed, and incubated for 1 h
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with avidin–biotin–peroxidase reagents (Elite Vectastain kit, Vector Labs, Burlingame, CA).
Diaminobenzidine (DAB, Sigma) was used as a chromagen to develop the reaction using 0.05%
of 3% H2O2 and nickel ammonium sulfate (2.5%, Sigma) was used to enhance the reaction.
Each of the above steps was separated by 3× 10 min washes in PBS. Sections were mounted
on glass slides and coverslipped with DPX.
2.7. Analysis of neurotoxicity
The loss of dopaminergic neurons was assessed by counting the number of TH-IR neurons
following immunostaining of brain sections. Twenty-four consecutive brain slices (35 µm),
which encompassed the entire SNc, were collected. A normal distribution of the number of
TH-IR neurons in the SNc was constructed based on the counts of 24 slices from C57BL/six
mice. Eight evenly spaced brain slices from saline or LPS-injected animals were immunos-
tained with an antibody against TH and counted. The distribution of the cell numbers from
each animal was matched with the normal distribution curve to correct for errors resulting from
the cutting. Samples were counted in a double-blind manner with stereology equipment, three
individuals, and the CAST system. Data were expressed as percent loss compared to saline-
injected controls. Conclusions were drawn only when the difference was within 5%.
2.8. Statistical analysis
The data are expressed as the mean ± S.E.M. and statistical significance was assessed with an
ANOVA followed by Bonferroni’s t-test. A value of P < 0.05 was considered statistically
significant.
3. Results
3.1. Sex differences in TH-IR neuronal loss after a single LPS injection
Male or female C57BL/six mice were treated with saline or LPS (5 mg/kg, i.p.) and then
sacrificed at the indicated time points. Brain sections (35 µm) were cut through the SN and
numbers of TH-IR neurons in the SN were counted. Consistent with our recent report (Qin et
al., 2007), the TH-IR neurons decrease at 5 months, and significant loss of TH-IR neurons was
observed at 7 months after a systemic single injection of LPS in male mice. In contrast, similar
treatment with LPS failed to produce any loss of DA neurons in female mice (Fig. 1A). Thus,
further experiments were performed to determine if repeated LPS injections can induce loss
of TH-IR neurons or motor deficits in female mice. Two to five consecutive LPS (5 mg/kg,
i.p.) or saline injections were given to female mice at monthly intervals and motor deficits by
rotarod test were measured at 7 months after the first injection. Fig. 1B shows that two or three
injections of LPS failed to alter the duration for mice to stay on the spinning rod, whereas
significant decreases in the rotarod ability were observed in mice received four to five LPS
injections compared with the corresponding saline-injected controls (Fig. 1B).
3.2. Motor behavioral changes after repeated LPS injections
Because four or five repeated LPS injections were required to produce motor function deficits
in female mice, another comparison by giving five repeated injections of LPS at either monthly
or weekly intervals was performed. The rationale for this study was due to the fact that repeated
LPS administration is known to cause tolerance. In monthly LPS-injected mice, rotarod test
showed delayed and progressive decreases in the duration in staying on the spinning rod. One
to 5 months after the first injection of LPS, there was no significant decrease in the rotarod
ability. However, progressive decreases in this motor function were observed 7–20 months
after the first injection of LPS (Fig. 2A). In contrast, mice receiving five-repeated weekly
injections of LPS failed to show any change in rotarod ability compared with the saline-injected
group (Fig. 2B). These data indicate that the time interval between LPS injections is critical
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for the manifestation of motor behavioral deficits. In addition to rotarod ability measurement,
we also determined the locomotor activities in mice 9 months after the first LPS injections.
Fig. 3 shows that total open-field activity, ambulatory activity and distance traveled decreased
in LPS-treated mice compared with saline-treated controls (Fig. 3).
To determine if the loss of motor function in LPS-injected mice was related to impairment in
the nigal–striatal dopamine activity, dopamine replacement experiment with L-dopa/carbidopa
treatment was conducted. Twelve months after the first LPS injections in five monthly regimen
of LPS treatment L-dopa/carbidopa (30 mg/3 mg/kg, i.p.) or saline were administered. Two
hours and 1 week after the injection, rotarod ability were measured. Fig. 4 shows that L-dopa/
carbidopa treatment restored LPS-induced deficits in rotarod ability at 2 h after the injection.
However, 1 week later, the effect of L-dopa/carbidopa was not observed. Results from this
replacement experiment suggest that LPS-induced loss of rotarod ability is related to the
deficiency in dopamine function in the nigal–striatal pathway. This speculation is supported
by the findings that LPS treatment caused progressive loss of nigral DA neurons (see below).
3.3. Progressive loss of nigral DA neurons after repeated LPS injections
To determine the nature of the nigral DA neuronal loss after five monthly repeated LPS
injections, both LPS- and saline-injected mice were sacrificed at different time points after the
first injection and TH-IR cell counts were performed. A 37% loss of TH-IR neurons in SNpc
was found in the LPS group compared with the vehicle (saline) group at the 9-month time point
( p < 0.05; Fig. 5A). The cell loss was progressive and reached 55% loss at 20 months ( p <
0.001; Fig. 5A). Compared with the saline-injected control mice, five monthly repeated LPS
injections induced a significant decrease in the TH immunoreactivity in the neuronal cell bodies
and neuronal fibers in the SNpc (Fig. 5B). It is obvious from the micrographs presented in Fig.
5B that there was also a significant degeneratative morphological alteration in the SN neurons
and neurites (insert in Fig. 5B). Morphological observation showed greatly enhanced
immunostaining of α-synuclein in the LPS-treated group than in the saline-treated group (Fig.
6A). In addition, immunostaining for CD45 and IL-6, both markers for activated microglia,
was increased in mice 20 months after the first LPS treatment (Fig. 6B and C). Microglial cells
had a branched appearance with increased reactive morphology in LPS-treated animals
compared to controls (Fig. 6B). The IL-6 immunohistochemistry is difficult to quantify based
on its wide-spread distribution, but future studies utilizing Western blots will determine the
extent of IL-6 increase in this brain region following the LPS injections.
4. Discussion
In this study, we have further characterized our previously reported neurodegeneration model
after a systemic injection of LPS in mice (Qin et al., 2007). A clear sex difference was found:
female mice were more resistant to LPS than male mice. Repeated LPS injections at monthly,
but not weekly intervals were required to cause both motor behavioral deficits and DA neuronal
loss. Time course studies revealed the time-dependent progressive nature of both rotarod ability
and loss of DA neurons. Pharmacological challenge with L-dopa/carbidopa was able to restore
the motor function deficits. Markers for α-synuclein, CD45, and IL-6 revealed that the LPS
injections gave rise to more wide-spread effects on the nigral region, including both neuronal
and glial correlates, and further suggested that the injections gave rise to a chronic increase in
neuroinflammation to the nigral region.
A delayed and time-dependent loss of nigral dopaminergic neurons was found in male (Qin et
al., 2007), but not in female mice (Fig. 1A), after a single systemic injection of LPS. This
finding in sex differences is similar to the previous report indicating that male mice are more
sensitive than female mice to MPTP-induced DA neuron degeneration (Miller et al., 1998).
These findings from animal studies are in concert with the fact that males outnumber females
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in PD patients (Shulman, 2007). One of the factors underlying the sex difference in response
to LPS is estrogen. It is well known that estrogen protects neurons against a vast variety of
toxic insults (Maggi et al., 2004; Wise, 2002). Estrogen has been shown to suppress the LPS-
induced activation of microglia by down-regulating inducible nitric oxide synthase (iNOS),
nitric oxide (NO), prostaglandin-E2 (PGE2) and matrix metalloproteinase (MMP)-9 activation
(Baker et al., 2004; Bruce-Keller et al., 2000; Drew and Chavis, 2000; Vegeto et al., 2000,
2001). Recently, Tenenbaum et al. (2007) reported that 17 beta-estradiol (E2) significantly
reduced LPS-induced increase in NO and TNFα (but not PGE2) production in glial cells.
Marotta et al. (2006) found that phytoestrogen treatment lowered levels of proinflammatory
cytokines including TNFα, IL-β and IL-6 and a higher level of TGF-β. Since female mice are
more resistant to LPS exposure, repeated injections of LPS are required to show behavioral
deficits and neuronal damage, possibly implying a protective effect of estrogen or other female-
specific factors on LPS-induced damages in vivo as well.
It is interesting to note the different responses in behavioral deficits and DA damage in weekly
vs. monthly injected paradigms (Fig. 2). These differences can be related to endotoxin
tolerance, a phenomenon whereby pre-exposure to endotoxin causes a reduced response to
subsequent challenge with endotoxin (Buckley et al., 2006;Munoz et al., 1991;Setrakian et al.,
1994). Tolerant animals dramatically reduced cytokine production, including TNFα, IL-1β
following an LPS challenge (Cavaillon and Adib-Conquy, 2006). It is likely that LPS injections
at weekly interval could elicit tolerance. Thus, in spite of repeated injections, nevertheless, the
net result is equivalent to a single injection.
Consistent with our previous report that a single systemic injection of LPS elicited a time-
dependent progressive loss of DA neurons in the SN (Qin et al., 2007), five monthly injection
of LPS resulted in similar decrease in DA neurons. In this study, we demonstrated that the
progressive loss of DA neurons was accompanied by a parallel decrease in rotarod ability in
LPS-injected mice. These results suggested that the neurodegeneration of DA neurons is
closely associated with the behavioral deficits. This notion was further supported by a
pharmacological challenge study using L-dopa/carbidopa. The rotarod ability was restored in
LPS-injected mice 2 h, but not 1 week, after L-dopa/carbidopa treatment (Fig. 4). Further, we
found that the LPS injection gave rise to a long-term increase in α-synuclein immunoreactivity
in the substantia nigra, further demonstrating a wide-spread reduction in DA function in these
neurons. Thus, peripheral LPS injection produced a rodent PD model, which reproduced
several important features in PD patients, such as a delayed progressive decrease in motor
function, loss of DA neurons in the SN and temporal relief of motor deficits after L-dopa/
carbidipa replacement therapy.
One of the salient features of systemic LPS PD model is the long-lasting effects of the motor
deficits and permanent loss of DA neurons in the SN. Most of the above-mentioned phenomena
were still observed 20 months after the first injection of LPS. These long-lasting effects in this
model are different from MPTP model in mice, which is known to be reversible 9–12 months
after the treatment (Hallman et al., 1985; Mitsumoto et al., 1998). As we previously reported
(Qin et al., 2004, 2007), inflammation played a key role in LPS-induced neurodegeneration,
which was mediated through cytokines, such as TNFα, produced by macrophages. The entry
of these pro-inflammatory cytokines into brain further activates microglia to produce more
pro-inflammatory factors, which continue to activate the same or neighboring microglia. Thus,
we postulate that once brain inflammation reaches a critical point, due to the dysregulated over-
activation of microglia either through the direct action of pro-inflammatory factors or indirect
action of reactive microgliosis results in the damage of neurons, a vicious, self-propelling cycle
occurs, which perpetuates the progression of neurodegeneration. Consistent with this
hypothesis, we observed increase in immunoreactivity of α-synuclein, CD45 and IL-6 even at
20 months after the first LPS injection. In view of the increasing evidence indicating a critical
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role of inflammation in the pathogenesis of PD (Hong, 2005), results presented in this study
suggest that the systemic LPS is a viable rodent PD model for studying the pathogenesis and
therapy of neurodegenerative diseases.
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The different response to LPS injection between male and female mice. Male or female C57BL/
six mice were treated with saline or LPS (5 mg/kg, i.p.) and then maintained under normal
conditions for the indicated time points. (A) Number of TH-IR neurons in the SN of control
and LPS-treated mice at different time points. Single-injected mice (male and female) were
sacrificed and brain sections (35 µm) were cut through the nigral complex. After
immunostaining with TH antibody, the number of TH-IR neurons in the SN was counted as
described in Section 2. Results are expressed as percentage of the corresponding saline controls.
(B) Multi-injected (once a month) female mice were made rotarod test at 7 months after the
first injection. *P < 0.05 and **P < 0.01 were compared to the saline controls (n = 5–10 per
group).
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The latency comparison between the monthly and weekly LPS injections in female mice on
the rotarod test. The female C57BL/six mice were injected with saline or LPS (5 mg/kg, i.p.)
weekly or monthly up to five times. Mice were maintained under normal conditions, and tested
on rotarod at different time points: (A) monthly injection group; (B) weekly injection group.
**P < 0.01 compared to the saline controls.
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Decreased locomotor behavior in five monthly LPS-injected mice. Female C57BL/six mice
were injected with saline or LPS (5 mg/kg, i.p.) monthly up to five times, maintained under
normal conditions, open-field test was performed on the 9th month after the first injection.
Total activity, ambulatory activity and distance traveled were recorded in the open-field test.
*P < 0.05 compared to the saline controls.
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L-dopa/carbidopa administration can reverse the reduction of rotarod motor ability. Mice
injected with five monthly saline and LPS were administed L-dopa/ carbidopa (30 mg/3 mg/
kg, i.p.) 12 months following the first saline or LPS treatment. Rotarod testing was done at 0
h, 2 h and 1 week after L-dopa/carbidopa injection. **P < 0.01 compared to the saline
controls. #P < 0.05 compared to the same group at 0 h or 1 week after L-dopa/carbidopa
administration.
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Delayed loss of nigral DA neurons following systemic LPS injection. Female C57BL/six mice
were monthly administered saline or LPS (5 mg/kg, i.p.) for five times, 9 or 20 months after
the first LPS injection, mice were sacrificed, brains were harvested and sectioned, and 24
sections (rostral to caudal: 4.52–5.36 mm posterior mm to bregma) were collected as described
in methods. Eight evenly spaced brain sections from saline or LPS-injected animals were
immunostained with an anti-TH antibody, and the number of TH-IR neurons in the SN was
counted. Data were expressed as percent loss compared to saline-injected controls. (A) Number
of TH-IR neurons in the SN in control and LPS-treated mice at 9 and 20 months. **P < 0.001,
compared with the corresponding control group. (B) Visualization of TH-IR neurons in the
substantia nigra and ventral tegmental area in saline and LPS-treated animals at 20 months.
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Enhanced immunostaining of α-synuclein, CD45 and IL-6 in LPS-treated mice. Female
C57BL/six mice were monthly administered saline or LPS (5 mg/kg, i.p.) for five times. At 20
months after the first saline or LPS treatment, brain sections were immunostained with α-
synuclein, CD45 and IL-6 antibody as described in methods. Five monthly repeated LPS
exposure significantly increased immunostaining of α-synuclein (A), CD45 (B) and IL-6 (C)
compared with the saline control group.
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